What is she best known for?
The fields of study she is best known for:
Her primary areas of investigation include Cell biology, Signal transduction, Anti-apoptotic Ras signalling cascade, Kinase and Cell surface receptor.
She interconnects Ras superfamily and Genetics in the investigation of issues within Cell biology.
The study incorporates disciplines such as Apoptosis, Programmed cell death, Tissue homeostasis, Intrinsic apoptosis and Effector in addition to Signal transduction.
Roya Khosravi-Far has included themes like Cancer cell, Cell type and Mitochondrion in her Programmed cell death study.
Roya Khosravi-Far works in the field of Kinase, namely MAPK/ERK pathway.
The MAPK/ERK pathway study which covers Molecular biology that intersects with Mitogen-activated protein kinase kinase and Mitogen-activated protein kinase.
Her most cited work include:
- Daxx, a novel fas-binding protein that activates jnk and apoptosis (1022 citations)
- Increasing complexity of Ras signaling (971 citations)
- Development of Human Protein Reference Database as an Initial Platform for Approaching Systems Biology in Humans (957 citations)
What are the main themes of her work throughout her whole career to date?
Roya Khosravi-Far mainly investigates Cell biology, Apoptosis, Cancer research, Programmed cell death and Signal transduction.
Her biological study spans a wide range of topics, including Transcription factor and Biochemistry.
Her work on Caspase is typically connected to c-Fos as part of general Apoptosis study, connecting several disciplines of science.
Her work deals with themes such as Tumor necrosis factor alpha, Immunology, Proteasome inhibitor, Carcinogenesis and PI3K/AKT/mTOR pathway, which intersect with Cancer research.
The Programmed cell death study combines topics in areas such as Cancer cell, Cancer, Tissue homeostasis and Mitochondrion.
Her Signal transduction research is multidisciplinary, incorporating elements of Molecular biology and Cell surface receptor.
She most often published in these fields:
- Cell biology (50.00%)
- Apoptosis (40.82%)
- Cancer research (43.88%)
What were the highlights of her more recent work (between 2012-2020)?
- Cancer research (43.88%)
- Apoptosis (40.82%)
- Cancer cell (19.39%)
In recent papers she was focusing on the following fields of study:
Roya Khosravi-Far focuses on Cancer research, Apoptosis, Cancer cell, Programmed cell death and PI3K/AKT/mTOR pathway.
Her research investigates the connection with Cancer research and areas like Cancer which intersect with concerns in FOXO3 and Transcription factor.
The various areas that Roya Khosravi-Far examines in her Apoptosis study include Fibrosarcoma, Immunology, Immune system and Systemic administration.
Her research on PI3K/AKT/mTOR pathway also deals with topics like
- Kinase, which have a strong connection to Molecular biology and Survivin,
- MAPK/ERK pathway which is related to area like LY294002.
As a part of the same scientific family, Roya Khosravi-Far mostly works in the field of Peptide, focusing on Necroptosis and, on occasion, Cell biology.
She studies Mitosis which is a part of Cell biology.
Between 2012 and 2020, her most popular works were:
- Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. (32 citations)
- Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier (27 citations)
- A Peroxidase Peroxiredoxin 1-Specific Redox Regulation of the Novel FOXO3 microRNA Target let-7 (20 citations)
In her most recent research, the most cited papers focused on:
Her main research concerns Cancer research, Imatinib, Tyrosine-kinase inhibitor, Chronic myelogenous leukemia and Imatinib mesylate.
The Cancer research study combines topics in areas such as Cancer cell, Cancer, Thyroid cancer and Apoptosis, Protein kinase B.
Her biological study spans a wide range of topics, including Kinase and MAPK/ERK pathway.
Her study in Proteasome inhibitor extends to Imatinib with its themes.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
